Dyne Therapeutics, Inc.

NasdaqGS:DYN Lagerbericht

Marktkapitalisierung: US$3.0b

Dyne Therapeutics Management

Management Kriterienprüfungen 2/4

Dyne Therapeutics CEO ist John Cox , ernannt in Mar 2024, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.036% der Aktien des Unternehmens, im Wert von $1.10M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.4 Jahre bzw. 5 Jahre.

Wichtige Informationen

John Cox

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführerless than a year
Eigentum des Geschäftsführers0.04%
Durchschnittliche Amtszeit des Managements3.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder5yrs

Jüngste Management Updates

Recent updates

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Nov 12
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 11

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14
Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04
We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29
We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

May 06

Geschäftsführer

John Cox (61 yo)

less than a year

Amtszeit

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He also serves as Atlas Advisor at Atlas Venture L.P. since 2024. He serves as...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
John Cox
CEO, President & Directorless than a yearkeine Daten0.036%
$ 1.1m
Romesh Subramanian
Co-Founder & Advisorno dataUS$4.37mkeine Daten
Richard Scalzo
Senior VP and Head of Finance & Administration4.3yrskeine Daten0.0058%
$ 174.3k
John Najim
Chief Technical Officer1.6yrskeine Datenkeine Daten
Oxana Beskrovnaya
Chief Scientific Officer3.4yrsUS$1.49m0.033%
$ 990.5k
Amy Reilly
Senior VP and Head of Corporate Communications & Investor Relations4.3yrskeine Datenkeine Daten
Daniel Wilson
Senior VP & Head of Legal4.4yrskeine Datenkeine Daten
Lucia Celona
Chief Human Resource Officerless than a yearkeine Datenkeine Daten
Debra Feldman
Chief Regulatory Affairs Officer4.5yrskeine Datenkeine Daten
Ashish Dugar
Chief Medical Affairs Officer3.8yrskeine Datenkeine Daten
Johanna Friedl-Naderer
Chief Commercial Officerless than a yearkeine Datenkeine Daten
Douglas Kerr
Chief Medical Officerless than a yearkeine Datenkeine Daten

3.4yrs

Durchschnittliche Betriebszugehörigkeit

56.5yo

Durchschnittliches Alter

Erfahrenes Management: DYNDas Führungsteam des Unternehmens gilt als erfahren (3.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
John Cox
CEO, President & Directorless than a yearkeine Daten0.036%
$ 1.1m
Sudhir Agrawal
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Edward Hurwitz
Independent Director6yrsUS$250.17k0%
$ 0
David Lubner
Independent Director4.7yrsUS$264.17k0.053%
$ 1.6m
Jason Rhodes
Independent Chairman6.9yrsUS$283.17k0%
$ 0
Dirk Kersten
Independent Director6yrsUS$262.67k0%
$ 0
Francesco Muntoni
Member of Scientific Advisory Board4.3yrskeine Datenkeine Daten
Louis Kunkel
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Nancy Andrews
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Catherine Stehman-Breen
Independent Director5.4yrsUS$253.92k0.088%
$ 2.7m
Charles Thornton
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Jeffrey Statland
Member of Scientific Advisory Board4.5yrskeine Datenkeine Daten

5.0yrs

Durchschnittliche Betriebszugehörigkeit

61yo

Durchschnittliches Alter

Erfahrener Vorstand: DYNDie Vorstandsmitglieder gelten als erfahren (5 Jahre durchschnittliche Amtszeit).